A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening

被引:33
|
作者
Grobbee, E. J. [1 ]
van der Vlugt, M. [2 ]
van Vuuren, A. J. [1 ]
Stroobants, A. K. [3 ]
Mundt, M. W. [4 ]
Spijker, W. J. [5 ]
Bongers, E. J. C. [6 ]
Kuipers, E. J.
Lansdorp-Vogelaar, I. [7 ]
Bossuyt, P. M. [8 ]
Dekker, E. [2 ]
Spaander, M. C. W. [1 ]
机构
[1] Erasmus Univ, Med Ctr, Dept Gastroenterol & Hepatol, Room Hs-312,Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands
[2] Acad Med Ctr Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[3] Acad Med Ctr Amsterdam, Dept Clin Chem, Amsterdam, Netherlands
[4] Flevoziekenhuis Almere, Dept Gastroenterol & Hepatol, Almere, Netherlands
[5] Reg Org Populat Screening South West Netherlands, Rotterdam, Netherlands
[6] Fdn Populat Screening Mid West, Amsterdam, Netherlands
[7] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands
[8] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands
关键词
OCCULT BLOOD-TESTS; 3; ROUNDS; PERFORMANCE; HEMOGLOBIN; TRENDS; YIELD; RISK;
D O I
10.1136/gutjnl-2016-311819
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective Colorectal cancer screening programmes are implemented worldwide; many are based on faecal immunochemical testing (FIT). The aim of this study was to evaluate two frequently used FITs on participation, usability, positivity rate and diagnostic yield in population-based FIT screening. Design Comparison of two FITs was performed in a fourth round population-based FIT-screening cohort. Randomly selected individuals aged 50-74 were invited for FIT screening and were randomly allocated to receive an OC -Sensor (Eiken, Japan) or faecal occult blood (FOB)-Gold (Sentinel, Italy) test (March-December 2014). A cut-off of 10 mg haemoglobin (Hb)/g faeces (ie, 50 ng Hb/mL buffer for OC-Sensor and 59 ng Hb for FOB-Gold) was used for both FITs. Results In total, 19 291 eligible invitees were included (median age 61, IQR 57-67; 48% males): 9669 invitees received OC-Sensor and 9622 FOB-Gold; both tests were returned by 63% of invitees (p = 0.96). Tests were non-analysable in 0.7% of participants using OC-Sensor vs 2.0% using FOB-Gold (p < 0.001). Positivity rate was 7.9% for OC-Sensor, and 6.5% for FOB-Gold (p = 0.002). There was no significant difference in diagnostic yield of advanced neoplasia (1.4% for OC-Sensor vs 1.2% for FOB-Gold; p = 0.15) or positive predictive value (PPV; 31% vs 32%; p = 0.80). When comparing both tests at the same positivity rate instead of cut-off, they yielded similar PPV and detection rates. Conclusions The OC-Sensor and FOB-Gold were equally acceptable to a screening population. However, FOB-Gold was prone to more non-analysable tests. Comparison between FIT brands is usually done at the same Hb stool concentration. Our findings imply that for a fair comparison on diagnostic yield between FIT's positivity rate rather than Hb concentration should be used.
引用
收藏
页码:1975 / 1982
页数:8
相关论文
共 50 条
  • [31] Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?
    Eunate Arana-Arri
    Isabel Idigoras
    Begoña Uranga
    Raquel Pérez
    Ana Irurzun
    Iñaki Gutiérrez-Ibarluzea
    Callum G. Fraser
    Isabel Portillo
    BMC Cancer, 17
  • [32] Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?
    Arana-Arri, Eunate
    Idigoras, Isabel
    Uranga, Begona
    Perez, Raquel
    Irurzun, Ana
    Gutierrez-Ibarluzea, Inaki
    Fraser, Callum G.
    Portillo, Isabel
    BMC CANCER, 2017, 17
  • [33] Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals
    Grobbee, Esmee J.
    Ha Wisse, Pieter
    Schreuders, Eline H.
    van Roon, Aafke
    van Dam, Leonie
    Zauber, Ann G.
    Lansdorp-Vogelaar, Iris
    Bramer, Wichor
    Berhane, Sarah
    Deeks, Jonathan J.
    Steyerberg, Ewout W.
    van Leerdam, Monique E.
    Spaander, Manon Cw
    Kuipers, Ernst J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (06):
  • [34] How many samples are needed when screening with faecal immunochemical tests for colorectal cancer?
    Young, G. P.
    Symonds, E. L.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 62 - 63
  • [35] Faecal immunochemical test outside colorectal cancer screening?
    Pin-Vieito, Noel
    Puga, Manuel
    Fernandez-de-Castro, Daniel
    Cubiella, Joaquin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (38) : 6415 - 6429
  • [36] Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population
    van Rossum, Leo G.
    van Rijn, Anne F.
    Laheij, Robert J.
    van Oijen, Martijn G.
    Fockens, Paul
    van Krieken, Han H.
    Verbeek, Andre L.
    Jansen, Jan B.
    Dekker, Evelien
    GASTROENTEROLOGY, 2008, 135 (01) : 82 - 90
  • [37] Faecal immunochemical test outside colorectal cancer screening?
    Noel Pin-Vieito
    Manuel Puga
    Daniel Fernández-de-Castro
    Joaquín Cubiella
    World Journal of Gastroenterology, 2021, (38) : 6415 - 6429
  • [38] Population-based colorectal cancer screening: comparison of two fecal occult blood test
    Zubero, Miren B.
    Arana-Arri, Eunate
    Pijoan, Jose I.
    Portillo, Isabel
    Idigoras, Isabel
    Lopez-Urrutia, Antonio
    Samper, Ana
    Uranga, Begona
    Rodriguez, Carmen
    Bujanda, Luis
    FRONTIERS IN PHARMACOLOGY, 2014, 4
  • [39] Impact of time between faecal immunochemical tests in colorectal cancer screening on screening results: A natural experiment
    Ribe, Sara G.
    Botteri, Edoardo
    Loberg, Magnus
    Randel, Kristin R.
    Kalager, Mette
    Nilsen, Jens Aksel
    Gulichsen, Elisabeth H.
    Holme, Oyvind
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (07) : 1414 - 1424
  • [40] Characteristics of nonparticipants in a randomised colorectal cancer screening trial comparing sigmoidoscopy and faecal immunochemical testing
    Botteri, Edoardo
    Hoff, Geir
    Randel, Kristin R.
    Holme, Oyvind
    de Lange, Thomas
    Bernklev, Tomm
    Aas, Eline
    Berthelsen, Mona
    Natvig, Erik
    Kirkoen, Benedicte
    Knudsen, Markus D.
    Kvaerner, Ane S.
    Schult, Anna L.
    Ursin, Giske
    Jorgensen, Anita
    Berstad, Paula
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (03) : 361 - 371